MSACL 

17. Combined Use of Immunoassay and 2-D LC/MS for the Detection and Identification of Metabolites From Biotherapeutic Pharmacokinetic Samples
Tue 12:18 PM - PosterSplash Track 2
Robert Murphy
CovX, Pfizer Biotherapeutics R&D
View Long Abstract
Peptides and monoclonal antibodies have both emerged as important therapeutic modalities, but each has challenges which limit their use. CovX has created a platform for rapid stoichiometric fusion of peptide pharmacophores onto a single antibody. These molecules, called CovX-Bodies, maintain both the pharmacologic properties of a given peptide and the pharmacokinetic properties of a monoclonal antibody. In this talk, we will demonstrate the combined use of immunoassay and two-dimensional liquid chromatography mass spectrometry (2DLC/MS) to investigate the antibody conjugates of Glucagon-like peptide-1 (GLP-1) and analogs for intact protein metabolite identification directly from mammalian serum.
Email: robert.murphy4@pfizer.com